Antibody-Drug Conjugates Targeting Resistance-Associated Signaling Pathways: Recent Advances and Future Perspectives

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Antibody-drug conjugates (ADCs) are a significant advancement in precision oncology.
• ADCs combine targeted antibody delivery with potent cytotoxic payloads for cancer treatment.
• Resistance to ADCs is a major challenge, leading to treatment failure.

Purpose of the Study:

• To review the molecular mechanisms driving resistance to antibody-drug conjugates.
• To examine the signaling pathways involved in ADC resistance.
• To evaluate novel therapeutic strategies to overcome ADC resistance.

Main Methods:

• Comprehensive literature review of signaling pathways in ADC resistance.
• Analysis of molecular mechanisms contributing to intrinsic and acquired ADC resistance.
• Evaluation of emerging therapeutic approaches to circumvent resistance.

Main Results:

• ADC resistance involves diverse mechanisms including antigen dynamics, drug efflux, DNA repair, and apoptosis evasion.
• Tumor cells utilize compensatory signaling networks to resist ADC therapy.
• Specific signaling cascades are critical drivers of ADC resistance phenotypes.

Conclusions:

• Elucidating signaling pathways is crucial for overcoming ADC resistance.
• Novel therapeutic strategies are being developed to target these resistance mechanisms.
• Optimizing ADC therapy requires a deep understanding of resistance biology to improve patient outcomes.